Ocugen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCGN research report →
Companywww.ocugen.com
Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
- CEO
- Shankar Musunuri
- IPO
- 2014
- Employees
- 95
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $460.39M
- P/E
- -6.08
- P/S
- 103.11
- P/B
- 75.07
- EV/EBITDA
- -7.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1483.85%
- Net Margin
- -1605.22%
- ROE
- -127987.50%
- ROIC
- -157.55%
Growth & Income
- Revenue
- $4.41M · 8.83%
- Net Income
- $-67,846,000 · -25.52%
- EPS
- $-0.23 · -15.00%
- Op Income
- $-62,916,000
- FCF YoY
- -25.53%
Performance & Tape
- 52W High
- $2.73
- 52W Low
- $0.79
- 50D MA
- $1.81
- 200D MA
- $1.50
- Beta
- 2.31
- Avg Volume
- 9.13M
Get TickerSpark's AI analysis on OCGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Zhang Junge | other | 66,929 |
| Apr 1, 26 | Zhang Junge | other | 112,205 |
| Apr 1, 26 | Zhang Junge | other | 15,000 |
| Apr 1, 26 | Zhang Junge | other | 112,205 |
| Apr 1, 26 | Zhang Junge | other | 15,000 |
| Apr 1, 26 | Zhang Junge | other | 66,929 |
| Mar 4, 26 | Johnson-Greene Treerita Essalima | other | 0 |
| Mar 4, 26 | Johnson-Greene Treerita Essalima | other | 0 |
| Mar 4, 26 | Johnson-Greene Treerita Essalima | other | 750,000 |
| Jan 2, 26 | Musunuri Shankar | other | 3,123,201 |
Our OCGN Coverage
We haven't published any research on OCGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OCGN Report →